FOXP3 and neoplasm: There was no significant difference in the distance between CD8+ and FoxP3+ T cells and tumor cells before preoperative treatment (Fig. 2d), and the average distance between CD8+ T cells and tumor cells was significantly shorter in the trastuzumab-exposed group (Fig. 2e).